CARGO Therapeutics, Inc. financial data

Symbol
CRGX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
835 Industrial Road, Suite 400, San Carlos, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Return On Equity -81.6 % -152%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39.4M shares
Common Stock, Shares, Outstanding 41.2M shares +3674%
Common Stock, Value, Issued 39K USD
Weighted Average Number of Shares Outstanding, Basic 41M shares +6770%
Weighted Average Number of Shares Outstanding, Diluted 41M shares +6770%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 30.5M USD +143%
General and Administrative Expense 10.3M USD +284%
Operating Income (Loss) -40.8M USD -168%
Net Income (Loss) Attributable to Parent -121M USD -148%
Earnings Per Share, Basic -0.87 USD/shares +95.9%
Earnings Per Share, Diluted -0.87 USD/shares +95.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 81.5M USD +38.7%
Marketable Securities, Current 294M USD
Assets, Current 380M USD
Property, Plant and Equipment, Net 10.6M USD
Operating Lease, Right-of-Use Asset 26.9M USD
Other Assets, Noncurrent 4.38M USD
Assets 422M USD
Accounts Payable, Current 7.17M USD
Employee-related Liabilities, Current 1.71M USD
Accrued Liabilities, Current 3.38M USD
Liabilities, Current 22.6M USD
Operating Lease, Liability, Noncurrent 26.6M USD
Other Liabilities, Noncurrent 225K USD -10%
Liabilities 49.2M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -279K USD
Retained Earnings (Accumulated Deficit) -181M USD
Stockholders' Equity Attributable to Parent 373M USD
Liabilities and Equity 422M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.1M USD -114%
Net Cash Provided by (Used in) Financing Activities 495M USD +1347%
Net Cash Provided by (Used in) Investing Activities -294M USD -47389%
Common Stock, Shares Authorized 500M shares +1624%
Common Stock, Shares, Issued 41.2M shares +3674%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -324M USD -670%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 82.1M USD +39.7%
Deferred Tax Assets, Valuation Allowance 30.4M USD +179%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 37M USD +226%
Operating Lease, Liability 28.2M USD
Depreciation 553K USD +160%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -36.1M USD -183%
Lessee, Operating Lease, Liability, to be Paid 46.8M USD
Property, Plant and Equipment, Gross 13.1M USD
Operating Lease, Liability, Current 1.64M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.22M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 4.68M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18.6M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.44M USD
Deferred Tax Assets, Operating Loss Carryforwards 2.28M USD +83%
Current Income Tax Expense (Benefit) 0 USD
Unrecognized Tax Benefits 1.23M USD +41.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.44M USD
Operating Lease, Payments 1.29M USD +185%
Additional Paid in Capital 554M USD
Interest Expense 1.6M USD -67.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares